Jasper Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-75.8M | $-71.3M | $-64.5M | $-37.7M | $-30.6M | $-31.7M |
| Depreciation & Amortization | $1.1M | $1.4M | $1.1M | $975.0K | $377.0K | — |
| Depreciation | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $6.7M | $6.6M | $5.2M | $4.1M | $1.0M | $1.2M |
| Net Cash from Operating Activities | $-77.2M | $-62.6M | $-52.1M | $-45.9M | $-33.7M | $-18.3M |
| Investing Activities | ||||||
| Capital Expenditures | — | — | — | — | — | — |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $5.0K | $-532.0K | $-267.0K | $-576.0K | $-2.4M | $198.3K |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $34.2M | $47.9M | $101.0M | $55.0K | $101.0M | $11.3M |
| Net Change in Cash | — | — | — | — | — | $-442.6K |
| Free Cash Flow | — | — | — | — | — | — |